These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20821294)

  • 1. Progress in the development of therapeutic antibodies targeting prion proteins and beta-amyloid peptides.
    He J; Zhang Y; Hong T
    Sci China Life Sci; 2010 Aug; 53(8):959-63. PubMed ID: 20821294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases.
    Tayebi M; Hawke S
    Immunol Lett; 2006 Jun; 105(2):123-6. PubMed ID: 16621033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons.
    White AR; Guirguis R; Brazier MW; Jobling MF; Hill AF; Beyreuther K; Barrow CJ; Masters CL; Collins SJ; Cappai R
    Neurobiol Dis; 2001 Apr; 8(2):299-316. PubMed ID: 11300725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibodies to synthetic fragment 95-123 of the prion protein protect neurons and astrocytes from beta-amyloid toxicity].
    Kamynina AV; Filatova MP; Koroev DO; Abramov AIu; Vol'pina OM
    Bioorg Khim; 2013; 39(2):131-40. PubMed ID: 23964513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineating common molecular mechanisms in Alzheimer's and prion diseases.
    Barnham KJ; Cappai R; Beyreuther K; Masters CL; Hill AF
    Trends Biochem Sci; 2006 Aug; 31(8):465-72. PubMed ID: 16820299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of conformational antibodies on dissociation of fibrillar amyloid beta (A beta 1-42) in vitro.
    Subramanian S; Madhavadas S; Balasubramanian P
    Indian J Exp Biol; 2009 May; 47(5):309-13. PubMed ID: 19579793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silent prions lying in wait: a two-hit model of prion/amyloid formation and infection.
    Hall D; Edskes H
    J Mol Biol; 2004 Feb; 336(3):775-86. PubMed ID: 15095987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
    Soto C; Estrada L; Castilla J
    Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against prion diseases.
    Kalinke U; Bach P; König M; Buchholz CJ
    Discov Med; 2006 Feb; 6(31):29-34. PubMed ID: 17234125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of vaccination approaches for the treatment of neurological diseases.
    Federoff HJ
    J Comp Neurol; 2009 Jul; 515(1):4-14. PubMed ID: 19399901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible proteopathies.
    Walker LC; Levine H; Mattson MP; Jucker M
    Trends Neurosci; 2006 Aug; 29(8):438-43. PubMed ID: 16806508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope-specific anti-prion antibodies upregulate apolipoprotein E and disrupt membrane cholesterol homeostasis.
    Tayebi M; David M; Bate C; Jones D; Taylor W; Morton R; Pollard J; Hawke S
    J Gen Virol; 2010 Dec; 91(Pt 12):3105-15. PubMed ID: 20797970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generating antibodies against the native form of the human prion protein (hPrP) in wild-type animals: a comparison between DNA and protein immunizations.
    Alexandrenne C; Wijkhuisen A; Dkhissi F; Hanoux V; Créminon C; Boquet D; Couraud JY
    J Immunol Methods; 2009 Feb; 341(1-2):41-9. PubMed ID: 19027745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to the scrapie protein decorate prion rods.
    Barry RA; McKinley MP; Bendheim PE; Lewis GK; DeArmond SJ; Prusiner SB
    J Immunol; 1985 Jul; 135(1):603-13. PubMed ID: 3923112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.
    Peretz D; Williamson RA; Kaneko K; Vergara J; Leclerc E; Schmitt-Ulms G; Mehlhorn IR; Legname G; Wormald MR; Rudd PM; Dwek RA; Burton DR; Prusiner SB
    Nature; 2001 Aug; 412(6848):739-43. PubMed ID: 11507642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
    Leliveld SR; Stitz L; Korth C
    Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.